Scholarlink

Aims <p> This study evaluates the ability of Rabeprazole (RAB) in counteracting cyclophosphamide (CP)-induced hepatotoxicity, focusing on its regulatory impact on key molecular signaling pathways, particularly AMPK/SIRT1, PI3K/Akt, TLR4/NF-κB, and MAPK, as well as its influence on NLRP3 inflammasome activation.</p> Main Methods <p>Rats were assigned into four distinct groups (n = 8 each): a control group administered distilled water; a CP group administered a single intraperitoneal dose of CP (200 mg/kg) on the seventh day; and two treatment groups pretreated orally with RAB (10 or 30 mg/kg/day)&#xa0;for ten days, with CP delivered on day 7. Biochemical, histological, immuno-histochemical, qRT-PCR, and western blotting procedures were conducted to evaluate liver function, oxidative status, and molecular signaling.</p> Key Findings <p>Rats exposed to CP showed marked&#xa0;increases in hepatic markers (ALT, AST), together with decreases in antioxidative markers (GSH, Nrf2, HO-1) and increases in MDA, MPO, iNOS, as well as pro-inflammatory markers represented by IL-6, TNF-α, IL-1β. Hepatic expression of AMPK, SIRT1, and PI3K/Akt was markedly suppressed, while TLR4, NF-κB p65, MAPK proteins, and NLRP3 were upregulated. RAB pretreatment dose-dependently restored hepatic enzyme levels, corrected redox imbalance, reduced cytokine release, and normalized gene and protein expression profiles. Histopathological improvements further corroborated the protective effect of RAB.</p> Significance <p>These results indicate that Rabeprazole may serve as an effective therapeutic option to reduce CP-induced liver injury through its multifaceted protective actions, highlighting the necessity for more extensive research in subsequent studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mechanistic insights into the hepatoprotective role of rabeprazole against cyclophosphamide-induced hepatotoxicity via AMPK/SIRT1 activation and suppression of TLR4/NF-κB and MAPK pathways

  • 期刊论文

  • 发表日期：

    2025年9月11日

查看全文
  • Asmaa Saleh,
  • Nahed A. Raslan,
  • Heba Mohammed Refat M. Selim,
  • Samar Ibrahim,
  • Ahmed Mohamed Farghly,
  • Abdel-Gawad S. Shalkami,
  • Lamiaa A. Salama,
  • Shaza M. Elhusseiny,
  • Shaimaa M. Hafez,
  • Nihal A. Mahmoud,
  • Asmaa I. Alwakeel,
  • Shimaa O. Ali,
  • Sherif A. Elsabbagh,
  • Manar Seleem Fouda,
  • Ahmed M. El-Dessouki

摘要

Aims

This study evaluates the ability of Rabeprazole (RAB) in counteracting cyclophosphamide (CP)-induced hepatotoxicity, focusing on its regulatory impact on key molecular signaling pathways, particularly AMPK/SIRT1, PI3K/Akt, TLR4/NF-κB, and MAPK, as well as its influence on NLRP3 inflammasome activation.

Main Methods

Rats were assigned into four distinct groups (n = 8 each): a control group administered distilled water; a CP group administered a single intraperitoneal dose of CP (200 mg/kg) on the seventh day; and two treatment groups pretreated orally with RAB (10 or 30 mg/kg/day) for ten days, with CP delivered on day 7. Biochemical, histological, immuno-histochemical, qRT-PCR, and western blotting procedures were conducted to evaluate liver function, oxidative status, and molecular signaling.

Key Findings

Rats exposed to CP showed marked increases in hepatic markers (ALT, AST), together with decreases in antioxidative markers (GSH, Nrf2, HO-1) and increases in MDA, MPO, iNOS, as well as pro-inflammatory markers represented by IL-6, TNF-α, IL-1β. Hepatic expression of AMPK, SIRT1, and PI3K/Akt was markedly suppressed, while TLR4, NF-κB p65, MAPK proteins, and NLRP3 were upregulated. RAB pretreatment dose-dependently restored hepatic enzyme levels, corrected redox imbalance, reduced cytokine release, and normalized gene and protein expression profiles. Histopathological improvements further corroborated the protective effect of RAB.

Significance

These results indicate that Rabeprazole may serve as an effective therapeutic option to reduce CP-induced liver injury through its multifaceted protective actions, highlighting the necessity for more extensive research in subsequent studies.